Furthermore, studies have shown that lower levels of MEG3 expression are associated with a higher WHO grade of tumour, older age at the time of diagnosis, low Karnofsky performance score (KPS), the presence of the wild‐type isocitrate dehydrogenase (IDH), tumour recurrence and poor overall survival.7 This evidence concerns the gene IDH1 and neoplasm.